GILD vs ZBIO · P/E 18, rev $7.80B vs rev $10.0M
Gilead Sciences Inc (GILD) versus Zenas BioPharma, Inc. Common Stock (ZBIO) — a side-by-side from cached financials, not a winner call.
Gilead Sciences Inc (GILD) is a drug manufacturers - general company listed on US.
Zenas BioPharma, Inc. Common Stock (ZBIO) is a biotechnology company listed on US.
Latest reported GILD revenue for 2026-06-30 was $7.80B. Net income was -$10.50B. Revenue was up 12.1% from 2026-03-31 to 2026-06-30. GILD currently screens at market cap $160.15B and trailing P/E 17.5.
Latest reported ZBIO revenue for 2025-12-31 was $10.0M. Net income was -$377.7M. Revenue was up 100.0% from 2024-12-31 to 2025-12-31. ZBIO currently screens at market cap $798.0M.
GILD currently screens at market cap $160.15B and trailing P/E 17.5. ZBIO currently screens at market cap $798.0M.
Not investment advice. Open the GILD and ZBIO stock pages for the full models.
Not investment advice.